Product Information |
Product name |
Tenofovir Alafenamide Fumarate / TAF |
CAS No. |
1392275-56-7 |
Molecular Formula |
2(C21H29N6O5P).C4H4O4 |
Molecular Weight |
1069.00 |
Quality Standard |
98% up, Medicine Grade |
Appearance |
White powder |
COA of Tenofovir Alafenamide Fumarate / TAF |
Usage
Function of Tenofovir Alafenamide Fumarate / TAF
Tenofovir
Alafenamide Fumarate / TAF is a novel nucleotide
reverse transcriptase inhibitor for the treatment of chronic hepatitis B virus
infection and compensatory liver disease.
Tenofovir alafluamine
fumarate is an oral prodrug of tenofovir (TFV), a modified version of the
commercially available drug tenofovir disoproxil fumarate (TDF). Compared with
TDF, TAF has a smaller clinical dose and is easier to enter the cell. The virus
acts more strongly and the adverse reactions are reduced.
API
TAF was approved by the
COS on November 10, 2016 for the treatment of adult patients with chronic
hepatitis B infection. PMDA was approved on December 19, 2016 and approved by
EMA in 2017.1.9, becoming the first hepatitis B drug approved for listing in
Europe in the past 10 years. Approved for the treatment of HIV infection, all
three drugs are based on tenofovir alafenamide fumarate.